B
3.82
0.04 (0.93%)
| Penutupan Terdahulu | 3.78 |
| Buka | 3.80 |
| Jumlah Dagangan | 483,329 |
| Purata Dagangan (3B) | 1,010,968 |
| Modal Pasaran | 217,359,296 |
| Harga / Pendapatan (P/E TTM) | 10.31 |
| Harga / Jualan (P/S) | 3.13 |
| Harga / Buku (P/B) | 1.73 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | 7.27% |
| Margin Operasi (TTM) | 77.90% |
| EPS Cair (TTM) | 0.060 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.25% |
| Nisbah Semasa (MRQ) | 9.24 |
| Aliran Tunai Operasi (OCF TTM) | 12.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 10.10 M |
| Pulangan Atas Aset (ROA TTM) | -0.42% |
| Pulangan Atas Ekuiti (ROE TTM) | 4.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Black Diamond Therapeutics, Inc | Menurun | Menurun |
AISkor Stockmoo
-1.0
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.00 |
|
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.63% |
| % Dimiliki oleh Institusi | 83.28% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 9.00 (Piper Sandler, 135.91%) | Beli |
| Median | 8.50 (122.81%) | |
| Rendah | 8.00 (Stifel, 109.70%) | Beli |
| Purata | 8.50 (122.81%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 4.08 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 18 Nov 2025 | 9.00 (135.91%) | Beli | 3.97 |
| Stifel | 16 Oct 2025 | 8.00 (109.70%) | Beli | 4.18 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Dec 2025 | Pengumuman | Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM |
| 02 Dec 2025 | Pengumuman | Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update |
| 06 Nov 2025 | Pengumuman | Black Diamond Therapeutics to Participate in Upcoming Investor Conferences |
| 06 Nov 2025 | Pengumuman | Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |